Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 15 Nov 2012 |
| Capital Increase in Genmab as a Result of Employee Warrant Exercise | 14 Nov 2012 |
| Genmab to Present at Jefferies Investor Conference in November | 8 Nov 2012 |
| Genmab Announces Financial Results for the First Half 2012 and Improves 2012 Financial Guidance | 7 Nov 2012 |
| CORRECTION: Genmab Announces Financial Results for the First Nine Months of 2012 and Improves 2012 Financial Guidance | 7 Nov 2012 |